Oppenheimer analyst Trevor Allred downgraded Theravance Biopharma (TBPH) to Perform from Outperform.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TBPH:
- Theravance Biopharma price target lowered to $15 from $27 at H.C. Wainwright
- Theravance Biopharma downgraded to Neutral from Buy at B. Riley
- Theravance Biopharma price target lowered to $21 from $40 at BTIG
- Midday Fly By: Target earnings hit the mark, Elliott invests $1B in Pinterest
- Theravance Biopharma falls 28% to $13.55 in pre-market trading